Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].
Wien Med Wochenschr
January 2004
Universitätsklinik für Klinische Pharmakologie, Währinger Gürtel 18-20, A-1090 Wien.
Because of fatal cases of rhabdomyolysis the HMG-CoA-reductase inhibitor cerivastatin had to be withdrawn from the global market in 2001. The high frequency and severity of cerivastatin-associated rhabdomyolysis caused concerns about the safety of the entire class of HMG-CoA-reductase inhibitors (statins). Still, the frequency of deadly incidents of rhabdomyolysis with cerivastatin was 16 to 80 times higher than with other statins.
View Article and Find Full Text PDF[Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Dtsch Med Wochenschr
February 2003
Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie, Stuttgart.
Ofloxacin was used in the treatment of 124 patients with bronchopulmonary diseases, the diseases of the biliary system and other infectious inflammatory diseases of the internal organs. The microbiological and pharmacokinetic indices as well as the immune status were investigated. The drug proved to be efficient in the treatment of 78.
View Article and Find Full Text PDF[Clinico-pharmacologic studies on pefloxacin].
Orv Hetil
March 1994
Fövárosi Onkormányzat Péterfy Sándor u. Kórház, A Belgyógyászati Osztály és Klinikai Farmakológia, Budapest.
The impact of liver impairment, renal insufficiency and age-related changes on the pharmacokinetics of pefloxacin was studied in 55 patients. The elderly patients were stratified into three age groups (61-70, 71-80 and above 81 years). The patients suffering from various infections were treated with oral or intravenous pefloxacin in a dose of 400 mg bid.
View Article and Find Full Text PDF[Clinico-pharmacologic considerations in Helicobacter pylori eradication therapy].
Z Gastroenterol
October 1993
Fachbereich Gastroenterologie, Deutsche Klinik für Diagnostik, Wiesbaden.
Problems and pitfalls of treatment regimens for eradication of Helicobacter pylori (Hp) are discussed from a clinical, pharmacological and microbiological point of view. Problems concerning the physician who treats the patient consists mainly in inappropriate indication and suboptimal knowledge of drugs, doses and duration of therapy against Hp. For successful triple therapy with complicated dosage protocols cooperation with and compliance by the patient is stressed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!